← THE EVIDENCE INDEXThe Study Library.
4,771 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
Showing studies that examined kale. Clear
People assigned to a diet, food or program and measured.
2 studies
2016 / Randomized, double-blind, placebo-controlled, crossover trial
In a randomized, double-blind, placebo-controlled crossover trial, 42 Japanese subjects consumed placebo or kale-containing food (7 g active-L or 14 g active-H) with a high-carbohydrate meal. Maximum plasma glucose concentrations (Cmax) were significantly lower for active-L (163±24 mg/dl) and active-H (162±23 mg/dl) compared with placebo (176±26 mg/dl; P<0.01). Glucose AUC0-2 h was also significantly lower for active-L (268±43 mg/h/dl) and active-H (266±42 mg/h/dl) versus placebo (284±43 mg/h/dl; P<0.05). No significant differences were found in postprandial plasma insulin levels, and no adverse events were observed.
Kondo S, Suzuki A, Kurokawa M, et al. Biomed Rep, 2016. PMID 27882216
2008 / Before-and-after intervention study
Thirty-two men with hypercholesterolemia consumed 150 mL of kale juice daily for a 12-week intervention period. Following supplementation, HDL-cholesterol increased by 27% (P<0.0001) and HDL-to-LDL ratio rose by 52% (P<0.0001), while LDL-cholesterol decreased by 10% (P=0.0007) and the atherogenic index dropped by 24.2% (P<0.0001). Glutathione peroxidase activity (P=0.0005) and serum selenium (P=0.0132) also increased, though malondialdehyde, BMI, and waist/hip circumferences showed no changes. Risk factor responses to kale juice supplementation were dependent on smoking status.
Kim SY, Yoon S, Kwon SM, et al. Biomed Environ Sci, 2008. PMID 18548846